Slipped capital femoral epiphysis (SCFE), Perthes' disease Musculoskeletal Diseases 1. Slipped Capital Femoral Epiphysis (SCFE) 2. Perthes' disease
Conditions
Interventions
Surveillance Cohort Study
A consecutive anonymised comprehensive surveillance cohort encompassing all UK cases of SCFE and Perthes’ disease. Each participating centre is asked to ente
Sponsors
University of Liverpool
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: SCFE: 1.Skeletally immature individuals 2. Radiological confirmation of displacement of the epiphysis relative to the metaphysis occurring at the proximal femoral physis 3. Newly presenting to secondary/ tertiary care during the study period with the above radiographic changes in either hip (i.e. patients will be included if the other side has been affected outside the study period, but the opposite hip is newly affected) 4. Undergoing surgical stabilisation during hospital admission 5. Resident within the England, Scotland or Wales Perthes: 1. Skeletally immature individuals. 2. Any of the following radiographic features within the femoral epiphysis. Features may be evident on plain radiographs, or MRI. 2.1. Flattening 2.2. Sclerosis 2.3. Fragmentation 2.4. Collapse 2.5. Reossification 3. Newly presenting to secondary/ tertiary care during the study period with the above radiographic changes in either hip (i.e. patients will be included if the other side has been affected outside the study period, but the opposite hip is newly affected) 4. Usually resident within the England, Scotland or Wales
Exclusion criteria
Exclusion criteria: SCFE: Previous attempts at stabilisation of the currently affected hip. Perthes: 1. Previous treatment for developmental hip dysplasia (not including double nappies) 2. Previous chemotherapy for malignancy 3. Previously diagnosed sickle cell anaemia 4. Multiple Epiphyseal Dysplasia (MED) or Spondyloepiphyseal Dysplasia (SED). 5. A known coagulopathy 6. Gauchers disease 7. Previous same-sided hip fracture 8. Hypothyroidism
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Anonymised Surveillance Cohort: Incidence of each disease within the UK is determined by expressing the cases seen as a proportion of the ‘at risk’ population. The ‘at risk’ population will be derived from government statistics. In order to ensure that the data collection mechanism is sensitive, a national independent network of orthopaedic surgical trainees (the BONE collaborative), and national routine administrative data provided by HSCIC is used to identify missing cases, and prompt their imputation into the cohort. Nested Consented Cohort Quality of Life is measured using the Pediatric Quality of Life Inventory (PEDSQL) at baseline, 3 months (SCFE only), 1 year (Perthes’ disease only) and 2 years (both diseases). | — |
Secondary
| Measure | Time frame |
|---|---|
| Anonymised Surveillance Cohort: SCFE 1. Radiographic Severity (Alpha angle) is assessed by reviewing radiographs that form part of the routine medical record at 2 years 2. Frequency of Avascular Necrosis is assessed by review of routine medical records at 3 months and 2 years, and by reviewing radiographs that form part of the routine medical record at 2 years 3. Frequency of Contralateral slip is assessed by review of routine medical records at 3 months and 2 years, and by reviewing radiographs that form part of the routine medical record at 2 years 4. Frequency of Chondrolysis is assessed by review of routine medical records at 3 months and 2 years, and by reviewing radiographs that form part of the routine medical record at 2 years Perthes' Disease 1. Radiographic Outcome (Stulberg Outcome) is assessed by review of routine medical records at 2 years, and by reviewing radiographs that form part of the routine medical record at 2 years 2. Frequency of contralateral disease is assessed by rview of routine medical records at 2 years, and by reviewing radiographs that form part of the routine medical record at 2 years Nested Consented Cohort Both Diseases (2 years) 1. Pain is measured using the Wong-Baker Faces Pain Score at baseline, 3 months (SCFE only), 1 year (Perthes’ disease only) and 2 years (both diseases) 2. Quality of life is measured using the EQ5DY questionnaire at baseline, 3 months (SCFE only), 1 year (Perthes’ disease only) and 2 years (both diseases) | — |
Countries
England, United Kingdom
Outcome results
None listed